CD19 and acute lymphoblastic leukemia: The approval of the CD19/CD3-targeting TCE blinatumomab, for B-cell precursor acute lymphoblastic leukaemia (ALL), demonstrated the clinical potential of this technology [2], setting off a wave of research to extend TCE therapies beyond haematologic malignancies and into solid tumours [3].